Widely present in the environment, arsenic trioxide has been identified as a genotoxic substance that poses a serious risk to public health. The genotoxic potential of arsenic at low allowable dosage levels is assessed in this study. Four groups of twelve adult rats each were created from the 48 total. Animals in Group I were used as controls Chromosome abnormalities found in bone marrow cells were used to assess the mutagenic potential of arsenic. Hematological parameters were also assessed. At 60 and 90 days, the percentage of microsomal degranulation in the hepatic fraction increased and the amounts of RNA and proteins considerably reduced (P < 0.01) in all three dosages given. was employed in order to assess hematological parameters White blood cells, lymphocytes, red blood cells, platelets, and mean erythrocyte hemoglobin concentration (MCHC) were all substantially lower (P≤0.05) in the arsenic treatment group than in the control group. Nevertheless, there are no appreciable changes in other measures such granulocytes, mean absolute count, hemoglobin (HGB), packed cell volume (PCV), mean corpuscular hemoglobin (MCH), and platelet count (PCT). We found that when rabbits get repeated therapeutic dosages of ivermectin over a brief period of time, Therefore, it is advised to take one dose over a few weeks. All of the treated animals showed a dose-dependent increase in chromosomal abnormalities such as fragmentation and breaking. The current study's findings demonstrated that long-term exposure to arsenic, even at low allowable dosage levels, has mutagenic and carcinogenic consequences, underscoring the metal's potential for genotoxicity.
